Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Q4 Revenues Up 12 Percent, Loss Narrows 65 Percent

NEW YORK, Feb. 18 (GenomeWeb News) - Caliper Life Sciences today reported a 12-percent increase in revenues for the fourth quarter while its net loss narrowed 65 percent.


Caliper had total revenues of $24 million for the period ended Dec. 31, 2004, up from $21 million for the same quarter last year.


The company said R&D spending fell to $4.7 million from $7.6 million year over year.


The company's net loss was $7 million, compared to $20 million in the year-ago period. Caliper said it took a $3.6 million non-cash charge in the quarter for closing the second of its three facilities in Mountain View, Calif. The company said it took the charge because of a "low probability of obtaining sublease income" from the facilities.


Caliper said it had around $9.4 million in cash and cash equivalents and $40 million in short-term marketable securities as of Dec. 31, 2004.

Looking ahead, the company said it expects first-quarter revenues to be between $17 million and $19 million, and to reach operating cash-flow breakeven point in the fourth quarter of 2005. Caliper posted $16.9 million in revenue during the first quarter of 2004.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.